Buprenorphine Should NOT Be Used for Migraine Treatment
Buprenorphine is not indicated, not recommended, and should be avoided for migraine treatment. The FDA-approved indication for buprenorphine is exclusively for opioid use disorder treatment 1, and current migraine treatment guidelines explicitly recommend against using opioids, including buprenorphine, for migraine management.
Why Buprenorphine Is Inappropriate for Migraine
Guideline Recommendations Against Opioids
The most recent and authoritative guidelines consistently advise against opioid use in migraine:
- The 2021 Nature Reviews Neurology guideline explicitly states that opioids should be avoided for acute migraine treatment due to questionable efficacy, considerable adverse effects, and risk of dependency 2
- The 2025 American College of Physicians guideline does not include any opioids in their recommended pharmacologic treatments for migraine prevention 3
- Multiple 2025 evidence-based guidelines for migraine treatment do not recommend opioids as part of standard care 4, 5
Real-World Harms Documented
The evidence shows significant problems with opioid use in migraine patients:
- 21.5% of people with active migraine in the US currently use opioids despite expert recommendations against this practice 6
- Opioid use in migraine is associated with higher migraine-related disability, higher interictal burden, more comorbidities, and increased emergency department visits 6
- Case reports document addiction to buprenorphine/naloxone when used for migraine self-treatment, even in healthcare professionals with pharmacologic knowledge 7
FDA-Approved Indication Does Not Include Migraine
All clinical trials supporting buprenorphine's FDA approval studied heroin-addicted subjects for opioid use disorder treatment 1. There are no controlled trials demonstrating efficacy or safety for migraine treatment.
What Should Be Used Instead
For Acute Migraine Treatment:
- First-line: NSAIDs (aspirin, ibuprofen, or diclofenac potassium) 2
- Second-line: Triptans 2
- Third-line: Ditans (lasmiditan) or gepants 2
- Adjunct: Prokinetic antiemetics (domperidone or metoclopramide) for nausea/vomiting 2
For Migraine Prevention:
The 2025 ACP guideline recommends evidence-based preventive medications, though specific agents are detailed in their full recommendations 3. Start at low doses and titrate gradually over 2-3 months to assess efficacy 3.
Critical Pitfall to Avoid
Do not confuse butorphanol (another opioid sometimes used off-label for migraine) with appropriate migraine treatment. One case report describes successful conversion from butorphanol to buprenorphine/naloxone 8, but this represents harm reduction in an already problematic situation—not an endorsement of buprenorphine for migraine. The case explicitly states that "evidence suggests that the harms of [butorphanol] use exceed the benefits" 8, and the same applies to all opioids in migraine management.
Bottom Line
Buprenorphine has no role in migraine treatment. Use evidence-based acute treatments (NSAIDs, triptans, ditans, or gepants) and consider preventive therapy when appropriate. The association between opioid use and worse migraine outcomes, combined with addiction risk and lack of efficacy data, makes buprenorphine contraindicated for this indication.